What is the best antifungal honey

By Isabella Storyclaire

last updated September 16, 2024

Contributions sourced from

Honey has an antifungal effect against Candida species

Abstract

The incidence of Candida infections is escalating worldwide. The serious nature of these infections is compounded by increasing levels of drug resistance. We report that certain honeys have significant antifungal activity against clinical isolates of Candida species. Importantly, the minimum inhibitory concentration of these honeys would be achievable in a clinical setting.

Introduction

Honey has been used as a medicine for thousands of years, and has been found to be an effective antimicrobial agent 1. This antimicrobial activity stems primarily from the production of hydrogen peroxide from glucose and oxygen by glucose oxidase, a bee-derived enzyme 2. Honey from certain species of Leptospermum flora native to Australia and New Zealand contains additional phytochemical components that further enhance its antibacterial activity 3. The precise nature of these components is yet to be identified.

Although several in vitro studies have demonstrated the antibacterial properties of honey 35, few have examined the action against fungi. The incidence of fungal infections is increasing in both the community and hospital environments, with Candida spp. among the leading organisms. Candida albicans causes oral infections, over 50% of candidaemia cases 69 and more than 90% of vaginal candidiasis 10, 11. Recently there have been increased reports of non-C. albicans Candida species in clinical studies. Candida glabrata has become the dominant non-C. albicans Candida species involved in bloodstream and vaginal infections 9, 1214, while Candida dubliniensis is often implicated in oropharyngeal candidiasis 15. Infection with non-C. albicans Candida species has important clinical implications, as many are resistant to conventional triazole-based antifungal therapy. Other conventional antifungal therapies are either toxic or of limited efficacy, and there is a growing need for new potent antifungal agents. The aim of the current study was to determine the efficacy of various honeys against clinical isolates of C. albicans, C. glabrata and C. dubliniensis.

Materials and methods

Clinical isolates of C. albicans, C. glabrata and C. dubliniensis were tested against four different honeys: an unprocessed Jarrah honey with hydrogen peroxide activity (total antibacterial activity (as described in 16) equivalent to 30.2% phenol 17); Medihoney Antibacterial Honey Barrier, a proprietary blend of Leptospermum and hydrogen peroxide honeys (phytochemical activity 18% phenol equivalent); Comvita Wound Care 18+, a pure Leptospermum honey (phytochemical activity 18% phenol equivalent); and an artificial honey, used to simulate the high sugar levels found in honey (7.5 g sucrose, 37.5 g maltose, 167.5 g glucose, and 202.5 g fructose in 85 ml of sterile water).

The minimum inhibitory concentration (MIC) of each honey was determined based on the NCCLS microdilution method 18. Fifty percent (w/v) stock solutions of honey in RPMI-1640 medium (with glutamine and without bicarbonate (Sigma)) were prepared immediately before each assay and filter sterilised through 0.2 m pore filters (Millipore). Stock solutions were further diluted with RPMI-1640 medium in 96-well microtitre plates to give final honey concentrations that increased in 1% (w/v) increments. Suspensions of Candida isolates were prepared in sterile 0.85% saline and transmittance at 530 nm was adjusted to 8088%. Suspensions were diluted in RPMI-1640 medium, and 25 l was added to each well of the microtitre plate immediately after preparation of the honey solutions, resulting in a final inoculum of 0.52.510³ cfu/ml. Following incubation at 35^oC for 24 h, the MIC was recorded as the lowest concentration of honey that prevented visible growth. Each Candida isolate was tested in duplicate and the assays were repeated on a separate day. The Mann-Whitney U test was used to evaluate statistically significant groups. Correlations were performed using the Spearman rank-order test.

Results

Results of the susceptibility of C. albicans, C. glabrata, and C. dubliniensis to various honeys are shown in Table 1. Jarrah honey was significantly more active against the three Candida species (P < 0.00001). The antifungal activities of the floral honeys were significantly greater than the artificial honey against C. albicans and C. glabrata (P < 0.002), but for C. dubliniensis, only Jarrah honey was significantly more active (P < 0.00001). C. dubliniensis was more susceptible to the osmotic effect of all honeys, and to the antifungal effects of Jarrah honey, exhibiting significantly lower MICs than the other species (P < 0.00001). C. glabrata, which is innately less susceptible to many conventional antifungals 19, was the least susceptible to the honeys tested (P < 0.00001).

Table 1

Susceptibility of Candida species to different honey types^a

.	Candida species (n) .
.	C. albicans (18) .	C. glabrata (10) .	C. dubliniensis (10) .
Jarrah	18.52.7**	29.92.8**	15.42.8**
Medihoney Antibacterial Honey Barrier	38.22.9**	43.14.2*	34.62.5
Comvita Wound Care 18 +	39.91.7**	42.62.8**	33.42.5
Artificial honey	42.61.8	44.72.7	34.32.4

.	Candida species (n) .
.	C. albicans (18) .	C. glabrata (10) .	C. dubliniensis (10) .
Jarrah	18.52.7**	29.92.8**	15.42.8**
Medihoney Antibacterial Honey Barrier	38.22.9**	43.14.2*	34.62.5
Comvita Wound Care 18 +	39.91.7**	42.62.8**	33.42.5
Artificial honey	42.61.8	44.72.7	34.32.4

Table 1

Susceptibility of Candida species to different honey types^a

.	Candida species (n) .
.	C. albicans (18) .	C. glabrata (10) .	C. dubliniensis (10) .
Jarrah	18.52.7**	29.92.8**	15.42.8**
Medihoney Antibacterial Honey Barrier	38.22.9**	43.14.2*	34.62.5
Comvita Wound Care 18 +	39.91.7**	42.62.8**	33.42.5
Artificial honey	42.61.8	44.72.7	34.32.4

.	Candida species (n) .
.	C. albicans (18) .	C. glabrata (10) .	C. dubliniensis (10) .
Jarrah	18.52.7**	29.92.8**	15.42.8**
Medihoney Antibacterial Honey Barrier	38.22.9**	43.14.2*	34.62.5
Comvita Wound Care 18 +	39.91.7**	42.62.8**	33.42.5
Artificial honey	42.61.8	44.72.7	34.32.4

Drug resistance profiles were available for 20 of the isolates. Twelve of these were either resistant or susceptible-dose dependent to itraconazole and/or fluconazole. All of these isolates were inhibited by honey, with no statistical relationship between antifungal susceptibility and sensitivity to honey (P > 0.05).

Discussion

Limited observations have found honey to have an inhibitory effect against C. albicans in vitro2022, however none of these studies used standardized honeys or assay methods. Only one published study has used honey with known phenol-equivalent activity to examine antifungal activity 23. In this study the effects of pasture honey were compared with Leptospermum honey against dermatophyte fungi. In accordance with the results of the current study the hydrogen peroxide-type honey was found to have a greater antifungal effect.

The current study found no statistical relationship between antifungal susceptibility and sensitivity to honey. This is of particular importance considering the increasing rate of resistance to azole drugs among Candida isolates 8, 24, 25, and the finding that azole-based prophylaxis increases the risk of infection with non-C. albicansCandida species, which may be less responsive to usual drug dosages 6, 24.

Although this study demonstrates the antifungal effect of honey in vitro there are some practical considerations for its use in vivo. Firstly, honey is limited to topical treatments, and could not be used to treat candidaemia, the most serious form of candidiasis. However, as the leading risk factor for bloodstream infection is colonization or infection of external sites, such as indwelling catheters, or the oral or vaginal mucosae 19, honey may be used prophylactically to prevent more serious infections. Whole honey placed directly around catheters was found to be at least as effective as povidone iodine 26 or mupirocin 27 in preventing exit site infection. Secondly, as honey is water soluble, it may be diluted or removed by body fluids, particularly saliva in the oral cavity. A pilot study by English et al. 28 found a significant reduction in mean plaque scores and bleeding sites in patients given a chewable honey leather; this same technique could be applied for the treatment of oral candidiasis. At other body sites, regular application of 100% honey would maintain a concentration well above the desired MIC. Honey could also be incorporated into a pessary for the treatment of vaginal candidiasis. Another practical issue is the presence of catalase in body fluids that has the potential to reduce hydrogen peroxide activity. However, case reports and clinical trials suggest sufficient activity is retained to allow honey to be effective in the clinical setting 29, 30. The results of the current study argue for controlled clinical trials to establish honey as a topical antifungal agent.

Acknowledgements

This work was supported by the Rural Industries Research and Development Corporation Honeybee Committee grant number US-128. Clinical isolates were kindly provided by Westmead Hospital Institute of Clinical Pathology and Medical Research, Sydney, Australia; and Mazandaran University of Medical Sciences, Sari, Iran. Honey samples were kindly provided by Medihoney Pty. Ltd., Queensland, Australia; Comvita Medical Ltd., Te Puke, New Zealand; and the Western Australian Beekeepers Association.

References

, .

Honey a remedy rediscovered

J R Soc Med

1989

,vol.

(pg.

384

385

)

, , .

The identification of inhibine, the antibacterial factor in honey, as hydrogen peroxide and its origin in a honey glucose-oxidase system

Biochim Biophys Acta

1963

,vol.

(pg.

)

The antibacterial activity of honey. 1. The nature of the antibacterial activity

Bee World

1992

,vol.

(pg.

)

, , .

The sensitivity to honey of Gram-positive cocci of clinical significance isolated from wounds

J Appl Microbiol

2002

,vol.

(pg.

857

863

)

, .

The use of honey as an antiseptic in managing Pseudomonas infection

J Wound Care

1999

,vol.

(pg.

161

164

)

, , ,et al.

The epidemiology of hematogenous candidiasis caused by different Candida species

Clin Infec Dis

1997

,vol.

(pg.

1122

1128

)

, , ,et al.

International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program

J Clin Microbiol

2001

,vol.

(pg.

3254

3259

)

, , , , .

National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program

Diagn Microbiol Infect Dis

1998

,vol.

(pg.

327

332

)

, , ,et al.

Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study

Eur J Clin Microbiol Infect Dis

2004

,vol.

(pg.

317

322

)

, , ,et al.

Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications

Antimicrob Agents Chemother

2003

,vol.

(pg.

)

, , ,et al.

Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole

Am J Obstet Gynecol

2001

,vol.

185

(pg.

363

369

)

, , , .

Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women

Am J Obstet Gynecol

2002

,vol.

187

(pg.

569

574

)

, .

Role of sentinel surveillance of candidaemia: trends in species distribution and antifungal susceptibility

J Clin Microbiol

2002

,vol.

(pg.

3551

3557

)

, , ,et al.

Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations

Am J Obstet Gynecol

1998

,vol.

178

(pg.

203

211

)

, , ,et al.

Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans

FEMS Yeast Res

2004

,vol.

(pg.

369

376

)

, , .

A survey of the antibacterial activity of some New Zealand honeys

J Pharm Pharmacol

1991

,vol.

(pg.

817

822

)

Antibacterial activity (hydrogen peroxide) of some Western Australian honeys

2005

National Committee for Clinical Laboratory Standards

Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard

2002

Wayne, PA

National Committee for Clinical Laboratory Standards

, , .

Epidemiology of Candida species infections in critically ill non-immunosuppressed patients

Lancet Infec Dis

2003

,vol.

(pg.

685

702

)

, , .

The antifungal action of three South African honeys on Candida albicans

Apidologie

2001

,vol.

(pg.

371

379

)

, , .

The antimicrobial spectrum of honey and its clinical significance

Infection

1992

,vol.

(pg.

227

229

)

, .

Antimicrobial activity of extracts of local cough mixtures on upper respiratory tract bacterial pathogens

West Indian Med J

2003

,vol.

(pg.

188

190

)

, , .

The sensitivity of dermatophytes to the antimicrobial activity of manuka honey and other honey

Pharm Sci

1996

,vol.

(pg.

471

473

)

, , ,et al.

The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance

Am J Med

1996

,vol.

100

(pg.

617

623

)

, , ,et al.

Epidemiology of clinical isolates of Candida albicans and their susceptibility to triazoles

Int J Antimicrob Agents

2002

,vol.

(pg.

472

475

)

Manuka honey for central vein catheter exit site care

Dialysis Clinic

1999

(pg.

397

398

)

, , ,et al.

Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients

J Am Soc Nephrol

2005

,vol.

(pg.

1456

1462

)

, , .

The effects of manuka honey on plaque and gingivitis: a pilot study

J Int Acad Periodontol

2004

,vol.